STAT+: Bristol Myers and Sanofi ordered to pay $834 million to Hawaii for withholding Plavix label
After years of litigation, a Hawaii court judge ordered Bristol Myers Squibb (BMY) and Sanofi…
Category: STAT+
Once again, senators want GAO to probe the role of PBMs in prescription drug pricing
In a bid to contain prescription drug prices, a pair of U.S. senators is re-introducing…
STAT+: Moncef Slaoui, departing Warp Speed, raises $250 million to test his R&D philosophy in a new company
Moncef Slaoui, who headed the Operation Warp Speed vaccine-development effort under the Trump administration, is…
STAT+: At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness
Not long ago, the name Flagship Pioneering was as likely to elicit an eye roll…
STAT+: Soaring mental health unicorns race to meet employer needs
Companies scrambling to provide employees with expanded mental health care options are propping up a…
STAT+: Pharmalittle: An arthritis drug reduced Covid-19 death rates; impatience grows over choosing FDA commissioner
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Experts encouraged by Denali’s early results in study of Hunter syndrome drug
A preliminary study of a medicine developed by Denali Therapeutics to treat Hunter syndrome, a…
STAT+: Amicus drug for Pompe disease falls short in key clinical trial, but company will push for approval
Amicus Therapeutics said Thursday that its drug for patients with Pompe disease, a rare genetic…
STAT+: With a legislative veto, Maryland’s prescription drug affordability board moves forward
Following a vote by the Maryland House of Delegates, the state now has all the…
STAT+: Scientists turn to machine learning to tackle one of gene therapy’s biggest challenges
As the world charges to vaccinate the population against the coronavirus, gene therapy developers are…
STAT+: Pharmalittle: Teva and Merck may help with Covid-19 vaccine production; $5 billion Gilead deal goes up in flames
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Drug maker agrees to plead guilty to hiding and destroying records before FDA inspection
A unit of Fresenius Kabi, a major supplier of infused and intravenously administered drugs, has…
STAT+: Zocdoc, staking its future on the promise of hybrid care, raises $150 million
Less than a year since Zocdoc reinvented itself as a telehealth platform in the face…
STAT+: Investing in Pacific Biosciences, SoftBank pays a 540% premium to offer price for entire company
SoftBank, the Japanese tech conglomerate famous for paying questionable sums to invest in startups, has…
STAT+: ‘A natural experiment’: Pandemic-driven drop in cancer screening may aid research on overdiagnosis
It’s counterintuitive, but catching cancer early isn’t always for the best. And the coronavirus pandemic…
STAT+: Drug maker will slash prices on cancer medicines to end price gouging probe in Europe
After months of deliberation, the European Commission has accepted an offer from Aspen Pharma to…
STAT+: Gilead’s Galapagos deal disintegrates, a black mark for CEO O’Day
The $5 billion deal that Gilead CEO Daniel O’Day presented as his signature move shortly…
.jpg)
STAT+: Pharmalittle: House Dems slip drug pricing proposal into Covid-19 relief bill; FDA grants emergency use for Lilly drug
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: House Democrats slip drug-pricing proposal into Covid-19 relief bill
WASHINGTON — House Democrats are expected to insert a controversial Medicaid drug pricing policy into…
STAT+: To delight of generic drug makers, federal appeals court tosses controversial ‘skinny labeling’ decision
In a surprising move, a federal appeals court panel may revisit a controversial decision that…
STAT+: Atul Gawande says Haven experience is helping shape his Covid-19 response work
The storied health tech startup Haven may have shuttered, but its famous former CEO, Atul…
STAT+: The Broad Institute’s new leader wants to ‘double down’ on biology
It has been an action-packed pandemic for the Broad Institute, the biomedical research center in…
STAT+: Pharmalittle: House to hold hearing on Covid-19 vaccine production; tug-of-war rages over who will be the next FDA commissioner
Rise and shine, everyone, another busy day is on the way. We can always tell,…
STAT+: In mid-stage study, KalVista pill halts swelling attacks caused by rare, genetic disease
KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced…
STAT+: Woodcock vs. Sharfstein: A head-to-head comparison of Biden’s top choices for FDA commissioner
WASHINGTON — President Biden will soon have to nominate someone to helm the Food and…
STAT+: Q&A: James ‘Jim’ Mullen on Editas, why he took the job as CEO, and his vision for the future
On Monday, Editas Medicines announced that veteran biopharma executive James “Jim” Mullen was expanding his…
STAT+: A move to crack down on human rights, environmental abuses puts European pharma on notice
A new European plan to develop legislation to hold companies accountable for human rights abuses…
STAT+: Dueling endorsements emerge for FDA commissioner: Woodcock or Sharfstein?
As the White House struggles to address the pandemic and other pressing health matters, a…
STAT+: Pharmalittle: South Africa halts rollout of AstraZeneca Covid-19 vaccine; Pfizer to cut vaccine production time in half
Good morning, everyone, and welcome to another working week. We hope the weekend was somehow…
STAT+: How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug
A science journal owned by the Alzheimer’s Association punished a trio of leading researchers after…
STAT+: WTO is urged to ease trade rules so low-income countries can access drugs and vaccines
More than 100 advocacy groups from dozens of countries are urging the World Trade Organization…
STAT+: FDA blasts Keytruda data for new breast cancer indication as ‘questionable, immature, and unreliable’
Merck (MRK) may have readily turned its Keytruda cancer drug into a medical and financial…
STAT+: Wife of CytoDyn’s chairman sold $2.6 million in company stock ahead of Covid-19 drug study results
The wife of CytoDyn’s chairman sold $2.6 million in company stock before CytoDyn is expected…
STAT+: Pharmalittle: J&J seeks emergency use for its coronavirus vaccine; Merck says parasite drug does not work on Covid-19
And so, another working week will soon draw to a close. Not a moment too…
STAT+: 5 burning questions on the business of big genetics based on 23andMe’s filing to go public
It seemed a foregone conclusion: Despite the early popularity of companies offering health and ancestry…
STAT+: The Pajama Interview: A conversation with Anne Wojcicki and Richard Branson
When consumer genetics firm 23andMe announced Thursday that it will go public through a deal…
Google expands its health goals with new wellness features for Pixel phones
Google is taking a bite out of another piece of the health care pie. On…
STAT+: Pharmalittle: Switzerland rejects AstraZeneca Covid-19 vaccine; McKinsey to pay $573 million over its role in opioid crisis
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: GSK to partner with CureVac on Covid-19 vaccine; Jazz to buy GW Pharma in $7.2 billion deal
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Explore STAT’s database of FDA-cleared AI tools
The Food and Drug Administration has cleared scores of AI tools for use in the…
STAT+: As the FDA clears a flood of AI tools, missing data raise troubling questions on safety and fairness
Artificial intelligence is the fastest-growing frontier in medicine, but it is also among the most…
STAT+: Pharmalittle: Russia’s Covid-19 vaccine appears effective; BioCryst stock is pursued by Reddit investors
Rise and shine, everyone, another busy day is on the way. Once again, however, events…
STAT+: Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call
Who (or what) is Vertex Pharmaceuticals going to buy? The question — asked many different…
STAT+: Could training AI to learn from patients give doctors a better understanding of the causes of pain?
For years, AI researchers have focused their energy on developing algorithms capable of sharpening or…
STAT+: Pharmacy benefit managers take heavy criticism from a new source: local officials
In what is being described as an unusual move, a Pennsylvania county is openly blaming…
STAT+: Amid a crush of Covid-19 research, scientists hone an AI tool to rapidly screen studies
Long before the pace of scientific publishing about Covid-19 broke land speed records, researchers were…
STAT+: Pharmalittle: AstraZeneca to boost Covid-19 vaccine supplies to EU; what comes next for Biogen’s Alzheimer’s drug?
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The FDA delayed its decision on Biogen’s Alzheimer’s drug. Now what?
The Food and Drug Administration’s decision to take three extra months to review Biogen’s controversial…
STAT+: Biden administration pumps brakes on signature Trump drug pricing proposal
WASHINGTON — The Biden administration has agreed to delay for a year the implementation of…
STAT+: Pharmalittle: J&J and Novavax vaccines are effective to varying degrees; FDA delays decision on Biogen Alzheimer’s drug
And so, another working week will soon draw to a close. Not a moment too…